HOME >> BIOLOGY >> NEWS
Memorial Sloan-Kettering Investigators

hat determines which patients respond to RA and which ones don't have identified a genetic difference between the two groups. APL patients who do well on RA treatment have leukemia that results from the fusion of two genes called PML and RAR-alpha (PML-RAR ), while the leukemia of patients who are resistant to RA is caused by a fusion of the genes PLZF and RAR-alpha (PLZF-RAR ).

To study these minute genetic differences further, Dr. Pandolfi and his colleagues developed two groups of mice: One group harbored the PML-RAR gene fusion, while a second group had the PLZF-RAR gene fusion. Both groups of mice developed APL similar to that seen in humans. In normal cells, certain proteins called transcription factors -- such as RAR -- turn on the expression of other genes with specific functions, such as controlling cell growth and maturation. Using advanced analytical techniques, Dr. Pandolfi's group showed that unlike RAR , proteins produced by the PML-RAR and PLZF-RAR gene fusions turned off, or "repressed," the expression of the cell's genes that normally prompt a cell to mature into a healthy, functioning white blood cell. Because these genes were turned off, the cells didn't mature, and leukemia developed. Moreover, the investigators found that PML-RAR and PLZF-RAR were acting as transcription repressors because of their ability to interact with other proteins. In PML- RAR , these interactions were broken apart by RA, while in PLZF-RAR they were insensitive to RA, explaining why retinoic acid works in some APL patients but not others.

Armed with this new knowledge, the MSKCC researchers set out to find ways to undo this chain of events. They knew that genetic material in a chromosome is tightly held together by proteins called histones. However, histones prevent individual gene expression. Previous studies of histones have shown that transcription repressors may work by favoring the place
'"/>

Contact: Kelli Stauning
stauningk@mskcc.org
212-639-3573
Memorial Sloan-Kettering Cancer Center
26-Jan-1998


Page: 1 2 3 4

Related biology news :

1. Veterinary Memorial Fund transforms grief into promise
2. Andres Vazquez-Torres honored with 2004 Merck Irving S. Sigal Memorial Award
3. American Society for Microbiology honors Timothy Yahr with 2004 Merck Irving S. Sigal Memorial Award
4. Childrens Memorial, TGen announce partnership
5. Webcast of NSF Director Rita Colwells Chafee Memorial Lecture
6. Director of Emory Vaccine Center to give Wistar Institutes 1999 Tadeusz J. Wiktor Memorial lecture
7. Snapshot of new drug marks a major advance by Memorial Sloan-Kettering researchers
8. Chern Memorial Award Presented To Wistar Institute Postdoctoral Fellow
9. APS announces four 2004 Young Investigators awards
10. EMBO Young Investigators 2000 2002
11. Investigators use guilt-by-association strategy to track potential cancer causing genes

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Memorial Sloan Kettering Investigators

(Date:10/18/2014)... suspected genetic conditions, a certain type of exome sequencing ... than traditional molecular diagnostic methods, according to a study ... released to coincide with the American Society of Human ... protein­coding region of the genome (the complete set of ... organism), has been rapidly applied in research settings and ...
(Date:10/17/2014)... release is available in German . ... of sperms every day in order to reproduce? And why ... the topic of the latest issue of the research journal ... The evolutionary biologist Steven Ramm from Bielefeld University Bielefeld has ... is not unusual for a female to copulate with several ...
(Date:10/17/2014)... To date, antidotes ... doctors are often limited to supportive therapy such as induced ... of drugs involved. So what can be done if a ... professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences at ... "The task was to develop an agent that could eliminate ...
Breaking Biology News(10 mins):Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Sperm wars 2Emergency aid for overdoses 2Emergency aid for overdoses 3
(Date:10/22/2014)... Oct. 22, 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, announced today that ... Notice of Allowance for a composition of matter patent ... difficile program, SYN-004. This is Synthetic Biologics, first ... U.S. and adds to the Company,s extensive C. ...
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... 20, 2014 Asterias Biotherapeutics, Inc. (NYSE ... signed a Notice of Grant Award (NGA) with ... October 1, 2014.  The NGA provides for the ... release of additional grant funds pursuant to the ... clinical development of Asterias, product, AST-OPC1. The grant ...
(Date:10/20/2014)... BOSTON , Oct. 20, 2014 ... commercialization company tackling big healthcare problems, announced today ... investment round, with participation from Invesco Perpetual, a ... be used to drive PureTech,s existing pipeline forward ... technologies. "PureTech has the scientific creativity to really ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
Cached News: